Literature DB >> 31342295

Tr-KIT/c-KIT ratio in renal cell carcinoma.

Sercan Ergün1, Diler Us Altay2, Sezgin Güneş3, Recep Büyükalpelli4, Süleyman Caner Karahan5, Leman Tomak6, Ümmet Abur7.   

Abstract

Truncated KIT (tr-KIT) is an alternative variant of c-KIT protein. Previous studies have clearly documented that c-KIT was associated with various oncogenic processes in RCC. However, the biological significance of tr-KIT in RCC development and progression remains unclear. So, it was aimed to investigate the possible association between RCC and tr-KIT which is thought to activate some oncogenic pathways. In this study, Kidney Cancer cDNA Array containing a total of 48 cDNA samples from the normal kidney tissues of 9 healthy subjects and kidney tumor tissues of 10 stage-1, 5 stage-2, 13 stage-3 and 11 stage-4 RCC patients was used for gene expression analysis. Real-Time PCR method was used to measure tr-KIT/c-KIT expression ratios. tr-KIT/c-KIT expression ratio was compared between tumor and normal samples, and statistically correlated with the clinical parameters of RCC patients. tr-KIT/c-KIT expression ratio was approximately 4-times higher in tumor samples than control ones (p = 0.001). Also, tr-KIT/c-KIT expression ratio was approximately two, three and six times higher in Fuhrman nuclear grades 2, 3 and 4 than normal, respectively (p = 0.009). Moreover, clear cell and papillary RCC has a significantly higher level of tr-KIT/c-KIT expression ratio than chromophobe RCC (p = 0.016). In the current study, it was stated for the first time that tr-KIT/c-KIT expression ratio was up-regulated in RCC tissues, and high tr-KIT/c-KIT expression ratio was correlated with more aggressive clinical features and poor patient prognosis. Our results suggest that increased tr-KIT/c-KIT expression ratio might be useful as a prognostic marker for RCC patients.

Entities:  

Keywords:  Fuhrman nuclear grade; Renal cell carcinoma; c-KIT; tr-KIT

Mesh:

Substances:

Year:  2019        PMID: 31342295     DOI: 10.1007/s11033-019-04985-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  45 in total

Review 1.  Signal transduction via the stem cell factor receptor/c-Kit.

Authors:  L Rönnstrand
Journal:  Cell Mol Life Sci       Date:  2004-10       Impact factor: 9.261

Review 2.  Hormonal regulation of c-KIT receptor and its ligand: implications for human infertility?

Authors:  Marília I Figueira; Henrique J Cardoso; Sara Correia; Cláudio J Maia; Sílvia Socorro
Journal:  Prog Histochem Cytochem       Date:  2014-11-01

3.  The stem cell factor (SCF)/c-KIT signalling in testis and prostate cancer.

Authors:  Henrique J Cardoso; Marília I Figueira; Sílvia Socorro
Journal:  J Cell Commun Signal       Date:  2017-06-27       Impact factor: 5.782

Review 4.  The SCF/c-KIT system in the male: Survival strategies in fertility and cancer.

Authors:  Henrique J Cardoso; Marília I Figueira; Sara Correia; Cátia V Vaz; Sílvia Socorro
Journal:  Mol Reprod Dev       Date:  2014-10-30       Impact factor: 2.609

5.  Expression of proto-oncogene c-kit in high risk prostate cancer.

Authors:  G Di Lorenzo; R Autorino; F P D'Armiento; C Mignogna; M De Laurentiis; M De Sio; M D'Armiento; R Damiano; G Vecchio; S De Placido
Journal:  Eur J Surg Oncol       Date:  2004-11       Impact factor: 4.424

Review 6.  Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.

Authors:  Robert Roskoski
Journal:  Biochem Biophys Res Commun       Date:  2005-10-04       Impact factor: 3.575

Review 7.  Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).

Authors:  Safdar Ali; Sher Ali
Journal:  Gene       Date:  2007-07-03       Impact factor: 3.688

8.  Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients - A GIRCG study.

Authors:  L Capelli; E Petracci; V Quagliuolo; L Saragoni; P Colombo; P Morgagni; D Calistri; A Tomezzoli; M Di Cosmo; F Roviello; C Vindigni; A Coniglio; V Villanacci; M Catarci; L Coppola; S Alfieri; R Ricci; C Capella; S Rausei; D Gulino; D Amadori; P Ulivi
Journal:  Eur J Surg Oncol       Date:  2016-05-30       Impact factor: 4.424

Review 9.  Therapeutic targeting of c-KIT in cancer.

Authors:  Leonie K Ashman; Renate Griffith
Journal:  Expert Opin Investig Drugs       Date:  2012-11-06       Impact factor: 6.206

10.  Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.

Authors:  Y Yarden; W J Kuang; T Yang-Feng; L Coussens; S Munemitsu; T J Dull; E Chen; J Schlessinger; U Francke; A Ullrich
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

View more
  2 in total

1.  Subtype of Neuroblastoma Cells with High KIT Expression Are Dependent on KIT and Its Knockdown Induces Compensatory Activation of Pro-Survival Signaling.

Authors:  Timofey Lebedev; Anton Buzdin; Elmira Khabusheva; Pavel Spirin; Maria Suntsova; Maxim Sorokin; Vladimir Popenko; Petr Rubtsov; Vladimir Prassolov
Journal:  Int J Mol Sci       Date:  2022-07-13       Impact factor: 6.208

Review 2.  Overview of current targeted therapy in gallbladder cancer.

Authors:  Xiaoling Song; Yunping Hu; Yongsheng Li; Rong Shao; Fatao Liu; Yingbin Liu
Journal:  Signal Transduct Target Ther       Date:  2020-10-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.